ESMO Share this item Dr. Sara Hurvitz is speaking on "Ribociclib and resistance to prior ET in the M3 and M7".
ESMO 2020: Dr. Michelino De Laurentiis: Ribociclib dose reduction on OS in M3 and M7 Dr. Michelino De Laurentiis is speaking on "Ribociclib dose reduction on OS in M3 and M7." ESMO 00:03:49
Talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali ? Dr. Joanna Kufel-Grabowska is discussing on "When talking about QoL, Kisqali also improved work productivity in M7, is that unique for Kisqali?" Kisqali Channel 00:03:08
In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor. What is your thought on this? Dr. Grazia Arpino is sharing her thoughts "In M3 trial, when used in 1 Line Kisqali showed PFS of 33.4m, one of the highest ever seen with a CDK4/6 inhibitor." Kisqali Channel 00:02:23
Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant? Dr. Tanja Fehm is discussing on "Monaleesa-3 clinical trial also included de novo patients and this is unique among studies with CDK4/6 inhibitors + fulvestrant?" Kisqali Channel 00:02:25
Does the use of Kisqali delay time to chemotherapy (in M3 trial)? And which numbers should we remember? Professor Janice Walshe is discussing "Does the use of Kisqali delays time to chemotherapy (in M3 trial) ? And which numbers should we remember?" Kisqali Channel 00:01:42
Can you describe more into depth the hormone resistant patient population included in M3 trial? Professor Mario Campone is describing more into depth the hormone resistant patient population included in M3 trial. Kisqali Channel 00:03:54
